Novo Nordisk’s Post

Novo moving forward

A week after European regulators greenlit Novo Holdings' $16.5 billion acquisition of CDMO Catalent, the FTC has now followed suit after some delay and public concerns from competing drugmaker Eli Lilly, among other groups. The deal will close in the coming days, and Novo Holdings will sell off three fill-finish sites in Italy, Belgium and Indiana to Novo Nordisk for $11 billion. From Anna Brown: #glp1 #glp1manufacturing #obesitydrugs #zepbound #wegovy #ozempic #mounjaro #novonordisk #novoholdings #elililly #catalent #ftc #cdmo

Novo Holdings has closed its $16.5 billion acquisition of Catalent Pharma Solutions 🤝 ✅ This comes after the deal received the greenlight from the Federal Trade Commission and European Commission 🏢 Novo Holdings plans to sell three of the CDMO giant's fill-finish sites to GLP-1 maker Novo Nordisk, drawing criticism from those worried it will limit competition. Read more on the deal below ⬇️ #Catalent #NovoNordisk #PharmaNews #CDMO

Novo Holdings has closed its $16.5 billion acquisition of Catalent Pharma Solutions 🤝 ✅ This comes after the deal received the greenlight from the Federal Trade Commission and European Commission 🏢 Novo Holdings plans to sell three of the CDMO giant's fill-finish sites to GLP-1 maker Novo Nordisk, drawing criticism from those worried it will limit competition. Read more on the deal below ⬇️ #Catalent #NovoNordisk #PharmaNews #CDMO

💊Pharma Deal Alert ⏰. 💰 Novo Holdings, the asset manager for the foundation that oversees Novo Nordisk, will acquire Catalent, a leading contract development and manufacturing organization (CDMO), for $16.5 billion. 💊 Here's the scoop: Novo Nordisk will recoup two-thirds of the cost by purchasing three Catalent fill-finish sites for $11 billion upfront. The strategic move is aimed at meeting soaring demand for its blockbuster drugs Wegovy® and Ozempic®. 📦The acquired sites in Bloomington, IN; Brussels, Belgium; and Anagni, Italy, employ more than 3,000 people and will strengthen Novo Nordisk's supply chain capabilities. 🚧 This acquisition reflects a broader trend in the industry, where companies are emphasizing strategic acquisitions and increasing M&A activity to stay ahead in a dynamic market landscape. ************************************* Source: https://buff.ly/49gBIcz Digitalize your M&A process now: https://buff.ly/3MABeE0 #mergersandacquisitions #duediligence #carveout #digitalsmart

See what you may have missed this week in pharma with our Editors' (re)View, where our editors discuss notable happenings in the industry. This week, Greg Slabodkin tackles Novo Holdings' $16.5B acquisition of Catalent which took the global contract development and manufacturing organization private. The buyout is a one-off the likes of which the industry may not see again. Read the full article with the link below! Catalent Pharma Solutions #NovoHoldings #NovoNordisk #Catalent #CatalentPharmaSolutions #acquisition #contractdevelopment #privateorganization #buyout #pharmaindustry #pharmanews #pharmamanufacturing #editorsreview https://lnkd.in/gasVRfm2

Novo Holdings has closed its $16.5 billion acquisition of Catalent Pharma Solutions 🤝 ✅ This comes after the deal received the greenlight from the Federal Trade Commission and European Commission 🏢 Novo Holdings plans to sell three of the CDMO giant's fill-finish sites to GLP-1 maker Novo Nordisk, drawing criticism from those worried it will limit competition. Read more on the deal below ⬇️ #Catalent #NovoNordisk #PharmaNews #CDMO

🚀 Novo Nordisk Secures European Green Light for Catalent Acquisition! 🌍 Novo Nordisk has officially received approval from the European Commission to acquire Catalent, Inc., a leading global contract development and manufacturing organization based in New Jersey. This strategic acquisition, which includes the purchase of three manufacturing sites from Novo Holdings, marks a significant enhancement of Novo Nordisk's manufacturing capabilities. 🔍 Key Highlights: - Approval received from multiple regulatory bodies. - Positive response from Catalent’s stockholders. - Anticipated completion by the end of 2024. This move not only strengthens Novo Nordisk's position in the contract development sector but also enhances its operational efficiency and market reach. With approximately 72,000 employees across 80 countries, Novo Nordisk is committed to advancing healthcare solutions for chronic diseases. Stay tuned as this acquisition unfolds! Click on the link for more details. #AcquisitionNews #Catalent #GlobalExpansion #HealthcareInnovation #NovoNordisk #Pharma #PharmaceuticalCompanies #MarketAccess #MarketAccessToday

At DBC Insights, we consistently monitor and analyze developments that shape the industry landscape. In recent years, the chemical distribution sector, particularly within the pharmaceutical market, has witnessed a marked trend toward consolidation. This trend is exemplified by significant acquisitions, such as IMCD Group's acquisitions of Signet in India (2020) and Eurochemo Pharma (2023), Azelis' purchase of S. Zhaveri, and, most recently, Barentz's strategic acquisition of Anshul Life Sciences. These acquisitions are not merely expansions; they represent a deliberate consolidation of resources, expertise, and market reach. This raises important questions: How will this consolidation impact the distribution market? In what ways will it alter the collaboration dynamics between principals and distributors? What perspectives might principals have on these evolving relationships? Feel free to comment below. For companies navigating these changes or looking to strategically position themselves in this evolving landscape, partnering with experienced advisors is crucial. Contact us today to explore how we can support your growth and strategic initiatives. #DBCInsights #ChemicalDistribution #Pharmaceuticals #MergersAndAcquisitions #StrategicGrowth #MarketConsolidation #IndustryTrends #AsiaPacific #SupplyChainStrategy #BusinessDevelopment #Strategy #ChemicalIndustry #ExpertInsights #PrivateEquity

🏭 𝗕𝗶𝗴 𝗰𝗵𝗮𝗻𝗴𝗲𝘀 𝗳𝗼𝗿 𝘁𝗵𝗲 𝗖𝗗𝗠𝗢 𝗶𝗻𝗱𝘂𝘀𝘁𝗿𝘆 𝗮𝗵𝗲𝗮𝗱. 🏭 Novo Holdings is set to finalize its $16.5 billion acquisition of Catalent, marking the largest biopharma M&A of 2024. With all regulatory hurdles cleared including FTC and European Commission approvals the deal is expected to close in the coming days. Read more in the article below 👇 #Mergersandacquisitions #Healthcare #CDMO